<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509220</url>
  </required_header>
  <id_info>
    <org_study_id>PBK-1701TC_P3</org_study_id>
    <nct_id>NCT03509220</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy</brief_title>
  <official_title>A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmbio Korea Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy, safety and tolerability of PBK-1701TC for bowel cleansing&#xD;
      before colonoscopy. Half the participants will receive PBK-1701TC and while the other will&#xD;
      receive standard oral preparation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, single-blinded, parallel, 2-treatment, multi-center&#xD;
      clinical trial. A total of 224 subjects will participate to this study and be assigned to the&#xD;
      test group or the control group. The subject will administer the first dose of assigned&#xD;
      investigational product in the evening prior to the scheduled colonoscopy. Subject will take&#xD;
      the second dose early in the morning of the colonoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful cleansing rate</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
    <description>%Patient with HCS-graded A or B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall cleansing rate</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
    <description>%Patient with each HCS-grade (A, B, C, D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean segmental cleansing score</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
    <description>Mean HCS-grade in each segment (5 Segments: Rectum, Sigmoid colon, Descending colon, Transverse colon, Ascending colon/cecum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cecal intubation time</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean colonoscopy withdrawal time</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
    <description>%Patient who have completed taking the investigational products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
    <description>Patient questionnaire about any patient discomfort related to investigational products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyp detection rate</measure>
    <time_frame>Two days (from day of first dosing to day of colonoscopy)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Colonic Diseases</condition>
  <condition>Intestinal Disease</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Digestive System Disease</condition>
  <arm_group>
    <arm_group_label>PBK-1701TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Day Split-Dosing Regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard oral preparation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2-Day Split-Dosing Regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBK-1701TC</intervention_name>
    <description>The subject will receive PBK-1701TC for colonoscopy.</description>
    <arm_group_label>PBK-1701TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard oral preparation</intervention_name>
    <description>The subject will receive the standard oral preparation for colonoscopy</description>
    <arm_group_label>Standard oral preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who is informed and give a consent in voluntary&#xD;
&#xD;
          -  Patients who is scheduled a colonoscopy&#xD;
&#xD;
          -  BMI 19≤and&lt;30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who participate in other interventional study or had participated within 30&#xD;
             days before screening&#xD;
&#xD;
          -  Pregnant or breast-feeding women who do not want to stop breast-feeding&#xD;
&#xD;
          -  Women of childbearing potential who do not agree with appropriate contraception during&#xD;
             this study&#xD;
&#xD;
          -  Patients who had experienced any hypersensitivity study drug or ingredient&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Arrhythmia with clinically significant findings from EKG&#xD;
&#xD;
          -  Congestive heart failure; NYHA functional class III or IV; unstable coronary artery&#xD;
             disease; myocardiac infarction history within 6 months&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Active infection except acute upper respiratory infection or local skin infection;&#xD;
             Fever (38 °C and higher) within 1 week before study administration&#xD;
&#xD;
          -  HIV infection and/or chronic hepatitis B or C&#xD;
&#xD;
          -  Patients who has a difficulty to participate because of severe nausea or vomiting&#xD;
&#xD;
          -  Suspected or confirmed inflammatory bowel disease, toxic colon or toxic megacolon, or&#xD;
             gastrointestinal obstruction or perforation; visible bleeding in colon&#xD;
&#xD;
          -  History of colon surgery and abdominal surgery within 6 month; need an emergency&#xD;
             surgery&#xD;
&#xD;
          -  Colonoscopy for the following use: treatment of bleeding from such lesions as vascular&#xD;
             malformation, ulceration, neoplasia, and polypectomy site (e.g.,electrocoagulation,&#xD;
             heater probe, laser or injection therapy); foreign body removal; decompression of&#xD;
             acute nontoxic megacolon or sigmoid volvulus; balloon dilation of stenotic lesions&#xD;
             (e.g., anastomotic strictures); palliative treatment of stenosing or bleeding&#xD;
             neoplasms (e.g., laser, electrocoagulation, stenting)&#xD;
&#xD;
          -  Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance&#xD;
&#xD;
          -  Severe dehydration risk (e.g., rhabdomyolysis, ascites)&#xD;
&#xD;
          -  History of hypersensitivity of drug or others&#xD;
&#xD;
          -  Alcohol or drug abuse within 6 months&#xD;
&#xD;
          -  Clinically significant underlying disease or medical history at investigator's&#xD;
             discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colonoscopy</keyword>
  <keyword>PBK-1701TC</keyword>
  <keyword>Bowel cleansing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

